Drug Giant Novo Nordisk to Acquire Dicerna for $3.3 Billion
- Posted by ISPE Boston
- On December 8, 2021
Dicerna Pharmaceuticals, a biopharmaceutical company focused on the development of investigational ribonucleic acid interference (RNAi) therapeutics, is being acquired by Danish drug giant Novo Nordisk for $38.25 per share in cash, which represents a total equity value of $3.3 billion and a premium of 80% to Dicerna’s closing price on November 17, 2021. Dicerna’s RNAi technology platform enables access to […]
Read More